Lv3
318 积分 2022-10-07 加入
Application of thrombopoietic agents in cancer therapy-induced thrombocytopenia: A comprehensive review
3小时前
待确认
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
7个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
9个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
9个月前
已完结
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
11个月前
已完结
Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity
1年前
已完结
EGFR Mutations and Lung Cancer
1年前
已完结
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
1年前
已完结
[Postoperative Recurrence of ROS1‒Positive Pulmonary Adenocarcinoma after 19 Years]
1年前
已关闭
Evolving roles of MET as a therapeutic target in NSCLC and beyond
1年前
已完结
皖公网安备34019202002308
